![EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_slide_teaser/public/2018-09/D1C8427E-8A1B-4977-85E5-49898050DEE7.png?itok=BMnn7QG8)
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis | Han | Cardiology Journal
![Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020 Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020](https://journals.sagepub.com/cms/10.1177/2632463620953677/asset/images/10.1177_2632463620953677-img2.png)
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
![De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis | Nature Reviews Cardiology De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis | Nature Reviews Cardiology](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41569-023-00901-2/MediaObjects/41569_2023_901_Fig1_HTML.png)
De-escalation or abbreviation of dual antiplatelet therapy in acute coronary syndromes and percutaneous coronary intervention: a Consensus Statement from an international expert panel on coronary thrombosis | Nature Reviews Cardiology
![EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com](https://d14d5nk8lue86f.cloudfront.net/s3fs-public/styles/large_slide_teaser/public/2019-09/C888853C-87A5-4681-8103-77803B64582C.png?itok=IZV364F0)
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
![NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología) NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)](https://www.hemodinamica.com/wp-content/uploads/2019/01/4.png)
NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)
![NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología) NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)](https://www.hemodinamica.com/wp-content/uploads/2019/01/5.png)
NUEVOS DATOS CLÍNICOS DE SYNERGY™ EN MÚLTIPLES ESCENARIOS CLÍNICOS. | SHCI - Sección de Hemodinámica y Cardiología Intervencionista de la SEC (Sociedad Española de Cardiología)
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk pati
![ISCHEMIC RISK MATTERS - RISK STRATIFICATION IN HIGH BLEEDING RISK (HBR) PATIENTS IMPLANTED WITH THE SYNERGY STENT: A POST-HOC ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal of the American College ISCHEMIC RISK MATTERS - RISK STRATIFICATION IN HIGH BLEEDING RISK (HBR) PATIENTS IMPLANTED WITH THE SYNERGY STENT: A POST-HOC ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal of the American College](https://www.jacc.org/cms/asset/7f971833-0216-41c2-b217-c840eef66b0b/fx1.jpg)
ISCHEMIC RISK MATTERS - RISK STRATIFICATION IN HIGH BLEEDING RISK (HBR) PATIENTS IMPLANTED WITH THE SYNERGY STENT: A POST-HOC ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal of the American College
Dual antiplatelet therapy after percutaneous coronary intervention in patients at high bleeding risk: A systematic review and meta-analysis | Han | Cardiology Journal
![JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents](https://www.mdpi.com/jcm/jcm-12-06711/article_deploy/html/images/jcm-12-06711-g001.png)
JCM | Free Full-Text | Evolution of Coronary Stent Platforms: A Brief Overview of Currently Used Drug-Eluting Stents
![3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions 3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions](https://www.jacc.org/cms/asset/36f95219-517e-4418-a593-37437769bf0d/gr6.jpg)
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation | JACC: Cardiovascular Interventions
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
![Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002870318302461-gr1.jpg)